阿霉素心肌病治疗研究进展  

Progress in the treatment of Doxorubicin cardiomyopathy

作　　者：余一平 郭航远[1] YU Yiping;GUO Hangyuan(Shaoxing University of Arts and Sciences,Shaoxing,Zhejiang 312000,China)

机构地区：[1]绍兴文理学院,浙江绍兴312000

出　　处：《医药前沿》2022年第31期43-46,共4页Journal of Frontiers of Medicine

基　　金：基于肠道微生态探索黄酒功能因子的健康养生作用(2020B33002);黄酒多酚联合粪菌移植在阿霉素诱导的线粒体分裂/融合异常中的作用和分子机制研究(82174204)。

摘　　要：阿霉素(DOX)是一种一线蒽环素醌类药物,是临床上广泛应用的有效抗癌药物。然而,DOX具有剂量依赖性和累积心脏毒性。除心力衰竭的金三角药物治疗外,有研究表明其他药物也可应用于DOX心脏毒性的预防治疗。因此,本文在总结DOX心脏毒性机制的基础上,了解治疗涉及最新的不同的信号通路,综述药物通过激活或抑制信号通路的靶点保护DOX诱导的心肌病的作用机制,以期发现更多的治疗预防策略。Doxorubicin hydrochloride(DOX)is a first-line anthracycline quinone drug that is widely used in clinical【】practice and effective anticancer drug.However,DOX is dose-dependent and cumulatively cardiotoxic.In addition to the Golden Triangle drug treatment for heart failure,studies have shown that other drugs can also be used for the preventive treatment of DOX cardiotoxicity.Therefore,on the basis of summarizing the mechanism of DOX cardiotoxicity,this article understands that the treatment involves the latest different signaling pathways,and discusses the mechanism of action of drugs to protect DOX-induced cardiomyopathy by activating or inhibiting the targets of signaling pathways,in order to discover more therapeutic prevention strategies.

关 键 词：综述 阿霉素心肌病 机制 信号通路 

分 类 号：R542.2[医药卫生—心血管疾病]